Nipro Corporation (FRA:5FA)

Germany flag Germany · Delayed Price · Currency is EUR
9.15
+0.15 (1.67%)
Last updated: Jun 3, 2026, 8:10 AM CET
Market Cap1.50B +17.5%
Revenue (ttm)3.60B +2.5%
Net Income73.66M +164.1%
EPS0.40 +164.1%
Shares Out n/a
PE Ratio20.36
Forward PEn/a
Dividend0.16 (1.76%)
Ex-Dividend DateMar 30, 2026
Volumen/a
Open9.15
Previous Close9.00
Day's Range9.15 - 9.15
52-Week Range7.30 - 9.20
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateMay 12, 2026

About Nipro

Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses. Its Medical-Related business develops, manufactures, and sells injection and infusion products, artificial organ-related products, functional products, dialysis products, cell cultures, hospital products, diabetic products, and pharmaceuticals comprising generic and kit products; and manufactures medical equipment, including dialysis medical device products; and operates dialysis and training centers. The company’... [Read more]

Industry Orthopedic, Prosthetic, and Surgical Appliances and Supplies
Founded 1947
Employees 39,168
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 5FA

Financial Performance

In fiscal year 2026, Nipro's revenue was 660.54 billion, an increase of 2.47% compared to the previous year's 644.59 billion. Earnings were 13.50 billion, an increase of 164.11%.

Financial numbers in JPY Financial Statements